Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
VICORE PHARMA AB is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being reviewed by 4 distinct examiners, which suggests a diverse range of perspectives on the company's patent applications. The prosecution is concentrated within 3 distinct art units, indicating that while the examiners vary, the technological focus remains relatively narrow within the biotechnology sector. This concentration allows for some consistency in the administrative handling of the applications even as individual examiner interactions differ. The presence of 4 distinct examiners ensures that each matter is evaluated independently.
MCDOWELL, BRIAN E is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With 4 pending office actions spread across 4 examiners, the workload is distributed such that no single individual holds a majority of the active cases. This distribution minimizes the risk of a single examiner's bottleneck affecting the entire portfolio. However, the involvement of 3 distinct art units for 4 actions implies that the portfolio may be crossing specific sub-specialties within the Biotechnology & Pharmaceuticals field. Practitioners should be mindful of varying art unit standards while managing these 4 pending office actions to ensure a cohesive strategy across the biotechnology sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18394422 | METHOD OF TREATING A PATIENT DIAGNOSED WITH AN INTERSTITIAL LUNG DISEASE | DUNN, LINDSAY MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 30d |
| 17912645 | IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1622 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 1624 | §103 | Final Rejection | 30d | Pending | Jan 09, 2024 |
| 18394422 | METHOD OF TREATING A PATIENT DIAGNOSED WITH AN INTERSTITIAL LUNG DISEASE | DUNN, LINDSAY MICHELLE | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18283487 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | CHAO, ALLEN | 1622 | §112 | Final Rejection | — | Pending | Sep 22, 2023 |
| 17912645 | IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | FETTEROLF, BRANDON J | 1626 | §103DP | Final Rejection | — | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial